BioPhenyx ApS

BioPhenyx is the first company in the world that quantitatively determines how genetic sequence variants (“what is coded?”) impact cell phenotypes (“what happens?”).

BioPhenyx exploits its proprietary, ground-breaking CRISPR-Select technology to determine effects of mutations and drugs in cell cultures, as reported in Nature Genetics.

CRISPR-Select provides fast and – importantly – conclusive results by introducing and quantitatively tracking a mutation of interest and neutral, internal control mutations.

BioPhenyx is currently serving customers ranging from big pharma to small-scale biotech enterprises to working with partners in the clinic.

Contact name:

Ole Bitsch-Jensen


Ole Maaløes Vej 3, 2200 Copenhagen N



If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 7172 1114

Copyright 2023 DANISH BIO – DANSK BIOTEK. All rights reserved.